From Molecule to Man: The Lifecycle of an MHRA Medicine

Hedley Rees draws on 35 years of supply chain experience to explain the real ‘Big Pharma system’ to us. He reveals that the MHRA is no more than a shell organisation. Staff have been leaving in droves since 2016, but who is replacing them?

Indeed, is anyone replacing them, or is the MHRA just running on largely unqualified, inexperienced skeleton staff, attempting to give us the appearance that they care about our safety? 

What is the MHRA, given its own admission that it is no longer a regulator but an enabler? An enabler for the same Big Pharma?

Typically, a vaccine can take anything from five to ten years, or up to decades, to produce, depending upon the disease and how complicated the situation is. The Covid-19 novel ‘vaccine’ took just under one year.  But how do novel ‘vaccines’ and new medicines like Paxlovid or Molnupiravir get to us?

UK Column was delighted to be given the opportunity to speak with Hedley Rees, Managing Consultant at PharmaFlow Limited, a British consultancy specialising in operations and supply chain management in life sciences. He has over 35 years of experience in industrial engineering, logistics and supply chain management., Previously he held senior positions at Bayer UK and British Biotech amongst others.

He recounts the journey of how a simple molecule becomes the medicine in your cupboard, together with the hurdles and obstacles it has to overcome in order to be tested, inspected, retested and reinspected in several iterations before it is delivered to your pharmacist or doctor.

We learn from him that all medicines have to go through strict and stringent tests at all stages before eventually being presented to the FDA, MHRA or other applicable regulator for approval.  Eleven years is the estimated time that any medicine will take to reach humans, with many failing along the way and even being rejected at the very last stage. It being such a costly and time-consuming process, you can understand how the pharmaceutical companies would be keen to cut corners; but at what cost to us? 

According to Bill Gates at the 2017 World Economic Forum launch conference for CEPI, safety and manufacturing work can be ‘cut out’. Hear it for yourself at this timestamp. Clearly, what Gates prophesied five years ago is exactly what Hedley Rees is observing within his own industry. He describes the arduous journey of some of our most well-known medicines and contrasts this with the rapid rollout of a novel, fragile experimental injection that we now know as the Covid-19 ‘vaccine’.

Following discussions at the G7 Health Ministers' Meeting hosted by the UK Government as part of its G7 presidency, the UK Government and industry leaders agreed to work towards a plan to develop and deploy high-quality diagnostics, therapeutics and vaccines within just one hundred days of a ‘new pandemic threat’ being identified.

The 100 Day Mission is the brainchild of Melinda Gates and Sir Patrick Vallance to ‘shortcut’ medicines and vaccines to all of us with little or no safety studies.

Among Hedley Rees' many books is Taming the Big Pharma Monster.

A subsequent UK Column interview with Hedley Rees is here.